The authors (Waleed F. Khalaf, MD; Meghan E. Caldwell, BS, MSN; and Nishitha Reddy, MD, MSCI) have disclosed that they have no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors.
Kerrin M. Green, MA, Assistant Managing Editor, Journal of the National Comprehensive Cancer Network
Ms. Green has disclosed that she has no relevant financial relationships.
Nicole B. Harrold, BS, Manager, Continuing Education and Grants
Ms. Harrold has disclosed that she has no relevant financial relationships.
Kristina M. Gregory, RN, MSN, OCN, Vice President, Clinical Information Operations
Ms. Gregory has disclosed that she has no relevant financial relationships.
SharaihaRZLebwohlBReimersL. Increasing incidence of enteropathy-associated T-cell lymphoma in the United States, 1973-2008. Cancer2012;118:3786–3792.
MurrayACuevasECJonesDBWrightDH. Study of the immunohistochemistry and T cell clonality of enteropathy-associated T cell lymphoma. Am J Pathol1995;146:509–519.
GaleJSimmondsPDMeadGM. Enteropathy-type intestinal T-cell lymphoma: clinical features and treatment of 31 patients in a single center. J Clin Oncol2000;18:795–803.
NovakovicBJNovakovicSFrkovic-GrazioS. A single-center report on clinical features and treatment response in patients with intestinal T cell non-Hodgkin's lymphomas. Oncol Rep2006;16:191–195.
DaumSUllrichRHeiseW. Intestinal non-Hodgkin's lymphoma: a multicenter prospective clinical study from the German Study Group on Intestinal Non-Hodgkin's Lymphoma. J Clin Oncol2003;21:2740–2746.
EganLJWalshSVStevensFM. Celiac-associated lymphoma. A single institution experience of 30 cases in the combination chemotherapy era. J Clin Gastroenterol1995;21:123–129.
WohrerSChottADrachJ. Chemotherapy with cyclophosphamide, doxorubicin, etoposide, vincristine and prednisone (CHOEP) is not effective in patients with enteropathy-type intestinal T-cell lymphoma. Ann Oncol2004;15:1680–1683.
SieniawskiMAngamuthuNBoydK. Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation. Blood2010;115:3664–3670.
DelabieJHolteHVoseJM. Enteropathy-associated T-cell lymphoma: clinical and histological findings from the International Peripheral T-Cell Lymphoma Project. Blood2011;118:148–155.
RadererMTrochMKiesewetterB. Second line chemotherapy in patients with enteropathy-associated T cell lymphoma: a retrospective single center analysis. Ann Hematol2012;91:57–61.
SenterPDSieversEL. The discovery and development of brentuximab vedotin for use in relapsed hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol2012;30:631–637.
ProBAdvaniRBriceP. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol2012;30:2190–2196.
ZelenetzADAbramsonJSAdvaniRH. NCCN Clinical Practice Guidelines in Oncology for Non-Hodgkin's Lymphomas. Version 1.2013. Available at: NCCN.org. Accessed January 16 2013.